DURABOLIN®
Composition:
Each ml of the oily solution contains 25 mg nandrolone phenylpropionate
General Description
Durabolin® is an injectable anabolic preparation. The pharmacologically active substance is nandrolone. The phenylpropionate ester gives the preparation duration of action of about one week after injection. Nandrolne is chemically related to the male hormone. Compared to testosterone, it has an enhanced anabolic and a reduced androgenic activity. This has been demonstrated in animal bioassays and explained by receptor binding studies. The low androgenicity of nandrolone is confirmed in clinical use. In the human, Durabolin has a nitrogen-saving action. This effect on protein metabolism has been established by metabolic studies and is utilized therapeutically in conditions where a protein deficiency exists such as during chronic debilitating diseases and after major surgery and severe trauma. In these conditions, Durabolin serves as a supportive adjunct to specific therapies and dietary measures. In women with disseminated mammary carcinoma, in selected cases Durabolin has been reported to produce objective regressions for many months. Furthermore, Durabolin has been shown to produce relief of bone pain in patients with osteoporosis. The similarly acting nandrolone ester, nandrolone decanoate (Deca-Durabolin), has been shown to increase bone mineral content in these patients.
Androgenic effects (e.g. virilisation) are relatively uncommon at the recommended dosages. Nandrolone lacks the C17 alpha-alkyl group which is associated with the occurrence of liver dysfunction and chol0065stasis.
Indication
- Chronic Obstructive Pulmonary Disease (COPD)
Contraindication
- Known or Suspected Carcinoma
Side Effects
- May cause virilisation, hoarseness, acne in women due to prolonged and frequent use with high dose
- Inhibition of Spermatogenesis
- Premature Epiphyseal Closure
Detail prescribing information:
|
|
|
